<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006604</url>
  </required_header>
  <id_info>
    <org_study_id>P1020A</org_study_id>
    <secondary_id>10037</secondary_id>
    <secondary_id>IMPAACT P1020A</secondary_id>
    <secondary_id>PACTG P1020-A</secondary_id>
    <secondary_id>ACTG P1020-A</secondary_id>
    <nct_id>NCT00006604</nct_id>
  </id_info>
  <brief_title>Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents</brief_title>
  <official_title>Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and -Experienced HIV-Infected Infants, Children, and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Maternal Pediatric Adolescent AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to find a safe and tolerable dose of the protease inhibitor
      (PI) atazanavir (ATV), with or without a low-dose boost of the PI ritonavir (RTV), when taken
      with other anti-HIV drugs in HIV infected infants, children, and adolescents.

      Advancements in anti-HIV drugs for HIV infected children and adolescents have been hard to
      make, in part because these patients often do not take the drugs as prescribed. ATV may be a
      better option because it is available in the form of powder which children and adolescents
      may be more willing to take regularly. Using a low dose of RTV as a boosting agent for ATV
      may also increase the chances of virologic response of highly active antiretroviral treatment
      (HAART)-experienced patients. This study aimed to find safe and tolerable doses of ATV with
      or without low-dose RTV boost in infants, children, and adolescents. For this study,
      participants were enrolled in the United States and South Africa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Advancements in HAART for HIV-infected children and adolescents are hindered by patient
      nonadherence. The availability of a powder formulation and the once-daily dosing schedule
      make ATV an attractive agent for improved adherence in pediatric treatment regimens. This
      study was designed to provide pharmacokinetic (PK) data to guide dosing recommendations for
      ATV, when given concurrently with or without low-dose RTV boost, in infants, children, and
      adolescents. During the study, the safety and tolerance of ATV (with or without low-dose RTV)
      were closely monitored, and virologic efficacy data were obtained.

      There were two parts to this study. Step I took place in the United States and South Africa,
      and were further divided into two sets of groups, Parts A and B. Part A participants received
      ATV only and Part B participants received ATV with low-dose RTV boost. All participants
      received ATV once a day with 2 other antiretroviral drugs (not provided by the study). In
      Part B only, participants received ATV with a low dose of RTV. Participants were placed into
      1 of 8 groups (Groups 1 to 4 for Part A; Groups 5 to 8 for Part B) with respect to age and
      study drug formulation. Participants in Groups 1 and 5 were infants between ages 3 months and
      1 day (91 days) and 2 years (less than or exactly 730 days) and took ATV in powder form.
      Participants in Groups 2, 3, 6, and 7 were children between 2 years and 1 day (731 days) old
      and 13 years old. Groups 2 and 6 received ATV in powder form, while Groups 3 and 7 received
      the capsule form. Patients in Groups 4 and 8 were adolescents between 13 years and 1 day old
      and 21 years old (not including the 22nd birthday) and took ATV in capsule form. As of
      01/02/2008 a new group, 5A was opened for enrollment. Participants in Group 5A were between 3
      months and 6 months old and took ATV in powder form plus a low-dose RTV booster.

      For each group, enrollment started with five participants per group. All participants were
      evaluated for PK and safety criteria, adjusting the dose of ATV until one was found that
      passes both sets of criteria. Then five additional participants were enrolled, with
      enrollment continuing for each group once all participants within that group meet the PK
      criteria. For groups receiving RTV (Groups 5 to 8), additional criteria must be met for each
      dose of ATV studied. In addition to the PK and safety evaluations, 24-hour post-dose
      concentrations (Cmin) were monitored in the first 10 participants enrolled for a dose of ATV
      before more participants were enrolled and studied at that same dose. Note that in Protocol
      Version 5.0, South African (S.A.) sites were allowed to enroll patients in study groups
      3,4,5,6,7,8. As a result, the study design has been modified to further stratify study groups
      3, 4, 5, 6, 7, 8 (at the final recommended dose), by country, i.e., U.S.A. versus S.A., such
      that 10 evaluable study subjects will be accrued in parallel to each study group-country
      cohort.

      Clinic visits will be every 4 weeks through Week 48, then every 8 weeks until the last
      participant to enroll in the study has reached Week 96 of his/her treatment. If, after 56
      weeks, a participant has a toxic reaction to a nucleoside/tide reverse transcriptase
      inhibitor (NRTI) in their medication regimen, the regimen may be changed to a different NRTI.
      At every visit, participants will undergo a complete medical history and physical exam,
      cardiac conduction evaluation, and urine and blood collection. Participants of childbearing
      age will have a pregnancy test performed at each visit.

      Step II will only be open to South African subjects who are virologically responding to
      treatment when the last enrollee into either part of Step I (Part A or Part B) has completed
      96 weeks of treatment (end of Step I) . All such participants will be given ATV in capsule
      form at the same dose they received at the end of Step I, as well as the other
      antiretrovirals they were receiving during Step I. Step II will continue until ATV is
      approved in South Africa and readily available by individual prescription, and participants
      will have a study visit every 12 weeks.

      Note that the following ATV doses were independently evaluated for each group during the
      dose-finding stage based on the description above: Group 1 ATV Powder (310mg/m^2, 620mg/m^2);
      Group 2 ATV Powder (310mg/m^2, 620mg/m^2); Group 3 ATV Capsule (310mg/m^2, 415mg/m^2,
      520mg/m^2); Group 4 ATV Capsule (310mg/m^2, 520mg/m^2, 620mg/m^2); Group 5 ATV Powder + RTV
      (310mg/m^2); Group 6 ATV Powder +RTV (310mg/m^2); Group 7 ATV Capsule + RTV (310mg/m^2,
      205mg/m^2); Group 8 ATV Capsule + RTV (310mg/m^2, 205mg/m^2); Group 5A ATV Powder + RTV
      (310mg/m^2). All these dosing groups are presented in Participant Flow groups to show the
      total number of participants enrolled, but only the participants enrolled at the final group
      doses are presented in the subsequent results.

      The following groups satisfied the safety and PK guidelines specified in the protocol: Groups
      3,4,6,7,8. Groups 5 and 5A did not satisfy the protocol-defined pharmacokinetic criteria.
      There was considerable inter-subject variability in systemic exposures in this age group,
      such that a dose escalation to 415mg/m^2 may have resulted in ATV exposures greater than
      90,000 ng*hr/mL in some children. Thus, a further dose increase in Groups 5 and 5A was not
      attempted.

      These are the final dose for each group: Groups 1 and 2 (Final dose was not established);
      Group 3 ATV Capsule (520mg/m^2); Group 4 ATV Capsule (620mg/m^2); Group 5 ATV Powder
      (310mg/m^2) + RTV; Group 6 ATV Powder (310mg/m^2) +RTV; Group 7 ATV Capsule (205mg/m^2) +
      RTV; Group 8 ATV Capsule (205mg/m^2) + RTV; Group 5A ATV Powder (310mg/m^2) + RTV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced a Safety Endpoint of Interest Attributed to ATV</measure>
    <time_frame>From study entry up to week 96</time_frame>
    <description>Total Bilirubin &gt;= 5.1xULN, ECG Events and Other Grade 3+ toxicities attributed to study treatment.
The AEs were graded by the clinicians according to the Division of AIDS (DAIDS) Toxicity Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. Relationship to study treatment was determined by the study team.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Died</measure>
    <time_frame>From study entry up to week 96</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC24h)</measure>
    <time_frame>Week 1 (Day 7) Intensive PK-24hr (Pre-Dose, 1, 2, 3, 4, 6, 8, and 12 hours post-dose and the following day at 24-hours post-dose)</time_frame>
    <description>Pharmacokinetics were determined by non-compartmental analysis and AUC0-24hr calculated by the linear trapezoidal method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Minimum Plasma Concentration (C24)</measure>
    <time_frame>Week 1 (Day 7) Intensive PK-24hr (Pre-dose, 1, 2, 3, 4, 6, 8, and 12 hours post-dose and the following day at 24-hours post-dose)</time_frame>
    <description>Pharmacokinetics were determined by non-compartmental analysis. C24 determined visually, except in the instance when the patient re-dosed the study medication prior to the 24 hour blood draw or the 24 hour level was not obtained, in which case the C24 was calculated from the elimination rate (ke) and the last measured concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Week 1 (Day 7) Intensive PK-24 hr (Pre-dose, 1, 2, 3, 4, 6, 8, and 12 hours post-dose and the following day at 24-hours post-dose)</time_frame>
    <description>Pharmacokinetics were determined by non-compartmental analysis and Maximum concentration (Cmax) was determined visually.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: Clearance (CL/F)</measure>
    <time_frame>Week 1 (Day 7) Intensive PK-24 hr (Pre-dose, 1, 2, 3, 4, 6, 8, and 12 hours post-dose and the following day at 24-hours post-dose)</time_frame>
    <description>Pharmacokinetics were determined by non-compartmental analysis and Apparent oral clearance (CL/F) was calculated as ATV dose divided by AUC0-24hr.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV RNA &lt;400 Copies/mL at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Over the duration of the protocol, the assay used to determine Plasma HIV RNA levels was transitioned from the Amplicor HIV-1 Assay to the Amplicor HIV-1 Monitor 1.5 UltraSensitive Assay (Roche Molecular Systems, Branchburg, NJ) to finally the Abbott Real time HIV-1 RNA assay. The assays were performed according to the manufacturer's instructions in a laboratory accredited by the College of American Pathologists and certified by the NIH Virology Quality Assurance (VQA) in the United States, and VQA certified in South Africa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV RNA &lt;400 Copies/mL at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Over the duration of the protocol, the assay used to determine Plasma HIV RNA levels was transitioned from the Amplicor HIV-1 Assay to the Amplicor HIV-1 Monitor 1.5 UltraSensitive Assay (Roche Molecular Systems, Branchburg, NJ) to finally the Abbott Real time HIV-1 RNA assay. The assays were performed according to the manufacturer's instructions in a laboratory accredited by the College of American Pathologists and certified by the NIH Virology Quality Assurance (VQA) in the United States, and VQA certified in South Africa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HIV RNA &lt;400 Copies/mL at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>Over the duration of the protocol, the assay used to determine Plasma HIV RNA levels was transitioned from the Amplicor HIV-1 Assay to the Amplicor HIV-1 Monitor 1.5 UltraSensitive Assay (Roche Molecular Systems, Branchburg, NJ) to finally the Abbott Real time HIV-1 RNA assay. The assays were performed according to the manufacturer's instructions in a laboratory accredited by the College of American Pathologists and certified by the NIH Virology Quality Assurance (VQA) in the United States, and VQA certified in South Africa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 Count (Cells/mm^3) From Baseline to Week 20</measure>
    <time_frame>Baseline, Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 Count (Cells/mm^3) From Baseline to Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 Count (Cells/mm^3) From Baseline to Week 96</measure>
    <time_frame>Baseline, Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 Percent From Baseline to Week 20</measure>
    <time_frame>Baseline, Week 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 Percent From Baseline to Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 Percent From Baseline to Week 96</measure>
    <time_frame>Baseline, Week 96</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Step I: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder) and two NRTIs.
ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step I: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder) and two NRTIs.
ATV Dose Tested: 310 mg/m^2, 620 mg/m^2; Final Dose: Not Established</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step I: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV Dose Tested: 310 mg/m^2, 415 mg/m2, 520 mg/m^2; Final Dose: 520 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step I: Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV Dose Tested: 310 mg/m^2, 520 mg/m^2, 620 mg/m^2; Final Dose: 620 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step I: Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step I: Group 5a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step I: Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV Dose Tested: 310 mg/m^2; Final Dose: 310 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step I: Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV Dose Tested: 310 mg/m^2, 205 mg/m^2; Final Dose: 205 mg/m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step I: Group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV Dose Tested: 310 mg/m^2, 205 mg/m^2; Final Dose: 205 mg/m^2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATV</intervention_name>
    <description>Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.</description>
    <arm_group_label>Step I: Group 1</arm_group_label>
    <arm_group_label>Step I: Group 2</arm_group_label>
    <arm_group_label>Step I: Group 3</arm_group_label>
    <arm_group_label>Step I: Group 4</arm_group_label>
    <arm_group_label>Step I: Group 5</arm_group_label>
    <arm_group_label>Step I: Group 5a</arm_group_label>
    <arm_group_label>Step I: Group 6</arm_group_label>
    <arm_group_label>Step I: Group 7</arm_group_label>
    <arm_group_label>Step I: Group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Administered as 100 mg capsules or oral solution.</description>
    <arm_group_label>Step I: Group 5</arm_group_label>
    <arm_group_label>Step I: Group 5a</arm_group_label>
    <arm_group_label>Step I: Group 6</arm_group_label>
    <arm_group_label>Step I: Group 7</arm_group_label>
    <arm_group_label>Step I: Group 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Step I:

          -  Age: 91 days to 21 years of age (not including the 22nd birthday).

          -  A confirmed diagnosis of HIV infection defined by the current definition of the
             IMPAACT Virology Core Laboratory Committee. More information about this criterion can
             be found in the protocol.

          -  Viral load greater than or equal to 5,000 copies/mL

          -  Any CDC clinical classification and immune status

          -  Antiretroviral treatment-naïve or -experienced study candidates must be able to add
             two new NRTIs as part of their new therapy in this protocol, or have genotypic
             evidence of sensitivity to two NRTIs (the NRTIs must be used in combinations
             recommended in the Guidelines for the Use of Antiretroviral Agents in Pediatric and
             Adolescent HIV Infection). More information about this criterion can be found in the
             protocol.

          -  Study candidates must show evidence of retained phenotypic sensitivity to ATV
             (resistance index ratio of less than 10) when the subject has failed (after at least
             12 weeks of therapy) two or more courses of PI containing regimens. More information
             about this criterion can be found in the protocol.

          -  Demonstrated ability and willingness to swallow study medications

          -  Study candidate, parent, or legal guardian must be able and willing to provide signed
             informed consent

          -  Female participants who are sexually active and able to become pregnant must use two
             methods of birth control. More information about this criterion can be found in the
             protocol.

          -  Males participating in the study must not attempt to impregnate a female, or
             participate in sperm donation programs. Males engaging in sexual activity that could
             lead to pregnancy must use a condom.

          -  Study candidates with a history of undefined syncope will require a complete cardiac
             conduction evaluation at screening [e.g., ECG, 24-hour monitoring (Holter), and
             exercise test (if age appropriate)]. This evaluation must rule-out any cardiac
             conduction abnormalities.

        Exclusion Criteria for Step I:

          -  Active hepatitis

          -  Presence of an acute serious/invasive infection requiring therapy at the time of
             enrollment

          -  Hypersensitivity to any component of the formulation of ATV

          -  Chemotherapy for active malignancy

          -  Pregnant or breastfeeding

          -  Any clinically significant diseases (other than HIV infection) or clinically
             significant findings during the screening medical history or physical examination
             that, in the clinician's opinion, would compromise the outcome of this study

          -  Any laboratory or clinical toxicity greater than Grade 2 at entry

          -  Documented history of cardiac conduction abnormalities or significant cardiac
             dysfunction

          -  History of undefined syncope that cannot be ruled out as related to cardiac conduction
             abnormalities

          -  Family history of prolonged QTc-interval syndrome, Brugada syndrome, or
             right-ventricular (RV) dysplasia

          -  Corrected QTc-Interval greater than 440 msec at screening

          -  Prolonged PR-Interval greater than 0.200 seconds (200 ms) on ECG at screening (study
             candidates greater than or equal to 13 years of age)

          -  PR-Interval greater than 98th percentile on ECG at screening (study candidates less
             than 13 years of age)

          -  Cardiac rhythm abnormalities:

               1. A type I second-degree atrioventricular (AV) block (Mobitz type I heart-block)
                  occurring during waking hours on ECG at screening

               2. A type II second-degree AV-block (Mobitz type II heart-block) at any time on ECG
                  at screening

               3. A complete AV-block at any time on ECG at screening

               4. A heart rate less than the 2nd percentile for age of the normal heart rate range
                  on ECG at screening

          -  Prolonged therapy with intravenous pentamidine for acute Pneumocystis Carinii
             Pneumonia (PCP) within three months of entry

        Inclusion Criteria for Step II:

          -  Any South African subject enrolled into either part of Step I, who is virologically
             successful by Week 96 of when the last study participant enrolled into the respective
             part of Step I

          -  Female participants who are sexually active and able to become pregnant must continue
             using two methods of birth control. More information about this criterion can be found
             in the protocol.

          -  Males who continue participation in the study must not attempt to impregnate a woman,
             or participate in sperm donation programs. Males engaging in sexual activity that
             could lead to pregnancy must use a condom.

        Exclusion Criteria for Step II:

          -  A South African participant who meets any of the criteria for treatment
             discontinuation by Week 96 of when the last participant enrolled into either part of
             Step I

          -  A South African participant who meets any of the exclusion criteria from Step I by
             Week 96 of when the last participant enrolled into either part of Step I
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>91 Days</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Rutstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Pediatric Infectious Diseases CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Usc La Nichd Crs</name>
      <address>
        <city>Alhambra</city>
        <state>California</state>
        <zip>91803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, UC San Diego CRS</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0672</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller Children's Hosp. Long Beach CA NICHD CRS</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900951752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of California San Francisco NICHD CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Colorado Denver NICHD CRS</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Univ. Washington DC NICHD CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida CDTC Ft Lauderdale NICHD CRS</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Regional HealthCare System, The Med. Ctr.</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Cook County Hosp. Chicago NICHD CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago (LCH) CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Univ. New Orleans NICHD CRS</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>701122699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Maryland Baltimore NICHD CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Univ. Baltimore NICHD CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center Ped. HIV Program NICHD CRS</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WNE Maternal Pediatric Adolescent AIDS CRS</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>016550001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers - New Jersey Medical School CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx-Lebanon Hospital Center NICHD CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10457</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Med. Ctr. Bronx NICHD CRS</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyu Ny Nichd Crs</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harlem Hosp. Ctr. NY NICHD CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Med. Univ., Dept. of Peds.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DUMC Ped. CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>277103499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia IMPAACT Unit CRS</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hosp. for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>191341095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital CRS</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Med. Ctr. Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital CRS</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp. of the King's Daughters, Infectious Disease</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hosp. of the Kings Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Research Institute CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Hosp. Ramón Ruiz Arnau, Dept. of Peds.</name>
      <address>
        <city>Bayamon</city>
        <zip>00956</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hosp. PR NICHD CRS</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soweto IMPAACT CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandukani CRS</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Pediatric_AEs_Over3MonthsAge_v03.pdf</url>
    <description>DAIDS Toxicity Table for Grading Severity of Pediatric (&gt; 3 mos of age) Adverse Experiences April, 1994.</description>
  </link>
  <reference>
    <citation>Rutstein RM, Samson P, Fenton T, Fletcher CV, Kiser JJ, Mofenson LM, Smith E, Graham B, Mathew M, Aldrovani G; PACTG 1020A Study Team. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A. Pediatr Infect Dis J. 2015 Feb;34(2):162-7. doi: 10.1097/INF.0000000000000538.</citation>
    <PMID>25232777</PMID>
  </reference>
  <reference>
    <citation>Kiser JJ, Rutstein RM, Samson P, Graham B, Aldrovandi G, Mofenson LM, Smith E, Schnittman S, Fenton T, Brundage RC, Fletcher CV. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. AIDS. 2011 Jul 31;25(12):1489-96. doi: 10.1097/QAD.0b013e328348fc41.</citation>
    <PMID>21610486</PMID>
  </reference>
  <reference>
    <citation>Aldrovandi G, Samson P, Fenton T, Schnittman S, Rutstein R, Ortiz A and the Pediatric AIDS Clinical Trial 1020A Group. Resistance to Atazanavir (ATV), Lopinavir (LPV), Tenofovir (TFV) Among Heavily Experienced Pediatric Patients. 12th International Symposium on HIV and Emerging Infectious Diseases in Toulon, France, June 2002.</citation>
  </reference>
  <reference>
    <citation>Aldrovandi G, Samson P, Fenton T, Schnittman S, and Rutstein R for the P1020A Team. Genotypic and phenotypic resistance to BMS232632 (Atazanavir-ATV), among heavily experienced pediatric patients who were ATV-naïve. 9th Conference on Retroviruses and Opportunistic Infections, February 24 - 28, 2002, Seattle, WA.</citation>
  </reference>
  <reference>
    <citation>Kiser J, Rutstein R, Aldrovandi G, Samson P, Graham B, Schnittman S, Smith M, Mofenson L, Fletcher C, and the PACTG 1020A Study Team. Pharmacokinetics of atazanavir/ritonavir in HIV-infected infants, children, and adolescents: PACTG 1020A. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2005.</citation>
  </reference>
  <reference>
    <citation>Kiser J, Rutstein R, Samson P, Graham B, Aldrovandi G, Mofenson L, Smith E, Zhang J, Biguenet S, Fletcher C, and the P1020A team. Atazanavir dosing conversion and pharmacokinetics in HIV-infected children switching from atazanavir powder to capsules. 12 th International Workshop on Clinical Pharmacology of HIV Therapy, Miami, Florida, April 2011.</citation>
  </reference>
  <reference>
    <citation>Meyers T, Rutstein R, Samson P, Violari A, Palmer M, Kiser J, Fletcher C, Fenton T, Mofenson L, Graham B, Schnittman S, Horga M, Aldrovandi G, for the PACTG 1020A Study. Treatment responses to atazanavir-containing HAART in a drug-naïve pediatric population in South Africa. 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2008.</citation>
  </reference>
  <reference>
    <citation>Rutstein R, Samson P, Aldrovandi G, Graham B, Schnittman S, Fletcher C, Kiser J, Smith E, Mofenson L, Fenton T, and the PACTG 1020A Study Team. Effect of atazanavir on serum cholesterol and triglyceride levels in HIV-infected infants, children, and adolescents: PACTG 1020A. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2005.</citation>
  </reference>
  <reference>
    <citation>Rutstein R, Samson P, Fenton T, Kiser J, Fletcher C, Schnittman S, Mofenson L, Smith E, Graham B, Aldrovandi G, PACTG 1020A Study. The NIH PACTG Protocol 1020A: ATAZANAVIR (ATV), +/- RITONAVIR in HIV-Infected Infants, Children and Adolescents. Presented at the 14th Conference on Retrovirus and Opportunistic Infection (CROI), Los Angeles, CA, February, 2007.</citation>
  </reference>
  <reference>
    <citation>Samson P, Rutstein R, Schnittman S, Ortiz A, Graham B, Fenton T, Aldrovandi G and the Pediatric AIDS Clinical Trials Group P1020A Study Team. Effects of Antiretroviral (ARV) Exposure and Genotypic (Geno) Mutations in Predicting Phenotypic Resistance (PRS) to Atazanavir (ATV), Lopinavir (LPV), and Tenofovir (TDF) in Patients Naïve to these Drugs. 13th International Symposium on HIV and Emerging Infectious Diseases, Toulon, France, June 2004.</citation>
  </reference>
  <reference>
    <citation>Samson P, Rutstein R, Fenton T, Kiser J, Fletcher C, Schnittman S, Mofenson L, Smith E, Graham B, Aldrovandi G, and the PACTG 1020A Study Team. Changes in cholesterol and triglyceride levels among pediatric subjects treated with atazanavir, with or without ritonavir boosting: the 1020A NIH PACTG protocol. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 2006.</citation>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2000</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <results_first_submitted>January 29, 2016</results_first_submitted>
  <results_first_submitted_qc>March 7, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2016</results_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Drug Administration Schedule</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Treatment Experienced</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date of First Enrollment: 16 November 2000; Date of Last Enrollment: 22 December 2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: ATV Dose: Powder (310mg/m^2)</title>
          <description>Group 1 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder) and two NRTIs.</description>
        </group>
        <group group_id="P2">
          <title>Group 1: ATV Dose: Powder (620mg/m^2)</title>
          <description>Group 1 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder) and two NRTIs.</description>
        </group>
        <group group_id="P3">
          <title>Group 2: ATV Powder (310mg/m^2)</title>
          <description>Group 2 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder) and two NRTIs.</description>
        </group>
        <group group_id="P4">
          <title>Group 2: ATV Powder (620mg/m^2)</title>
          <description>Group 2 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder) and two NRTIs.</description>
        </group>
        <group group_id="P5">
          <title>Group 3: ATV Capsule (310mg/m^2)</title>
          <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They will received ATV (capsule) and two NRTIs.</description>
        </group>
        <group group_id="P6">
          <title>Group 3: ATV Capsule (415mg/m^2)</title>
          <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.</description>
        </group>
        <group group_id="P7">
          <title>Group 3: ATV Capsule (520mg/m^2)</title>
          <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
Note: This is the final recommended dose for this group.</description>
        </group>
        <group group_id="P8">
          <title>Group 4: ATV Capsule (310mg/m^2)</title>
          <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.</description>
        </group>
        <group group_id="P9">
          <title>Group 4: ATV Capsule (520mg/m^2)</title>
          <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.</description>
        </group>
        <group group_id="P10">
          <title>Group 4: ATV Capsule (620mg/m^2)</title>
          <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
Note: This is the final recommended dose for this group.</description>
        </group>
        <group group_id="P11">
          <title>Group 5: ATV Powder (310mg/m^2) + RTV</title>
          <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
Note: This is the final recommended dose for this group.</description>
        </group>
        <group group_id="P12">
          <title>Group 5a: ATV Powder (310mg/m^2) + RTV</title>
          <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
Note: This is the final recommended dose for this group.</description>
        </group>
        <group group_id="P13">
          <title>Group 6: ATV Powder (310mg/m^2) + RTV</title>
          <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
Note: This is the final recommended dose for this group.</description>
        </group>
        <group group_id="P14">
          <title>Group 7: ATV Capsule (310mg/m^2) + RTV</title>
          <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.</description>
        </group>
        <group group_id="P15">
          <title>Group 7: ATV Capsule (205mg/m^2) + RTV</title>
          <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
Note: This is the final recommended dose for this group.</description>
        </group>
        <group group_id="P16">
          <title>Group 8: ATV Capsule (310mg/m^2) + RTV</title>
          <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.</description>
        </group>
        <group group_id="P17">
          <title>Group 8: ATV Capsule (205mg/m^2) + RTV</title>
          <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
Note: This is the final recommended dose for this group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="21"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="5"/>
                <participants group_id="P10" count="25"/>
                <participants group_id="P11" count="21"/>
                <participants group_id="P12" count="12"/>
                <participants group_id="P13" count="26"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="24"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="13"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="22"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="14"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="19"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="6"/>
                <participants group_id="P15" count="10"/>
                <participants group_id="P16" count="5"/>
                <participants group_id="P17" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Met study objective - no further FU</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization entry error-no RX, no FU</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe debilitation, unable to continue</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="2"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subj/Parent not able to get to clinic</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subj/parent not willing to adhere to req</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="3"/>
                <participants group_id="P17" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants accrued and treated at the dose ultimately selected for their groups.
NOTE: (1) Final Dose not established for Grps 1, 2; (2) Grp 5a started with n=12, but (1) participant inadvertently enrolled,never received ATV, final n=11; (3) Grp 8 started with n=15, but (1) participant inadvertently enrolled, never received ATV, final n=14.</population>
      <group_list>
        <group group_id="B1">
          <title>Step I: Group 3 (ATV Final Dose: 520mg/m^2 Capsule)</title>
          <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
        </group>
        <group group_id="B2">
          <title>Step I: Group 4 (ATV Final Dose: 620mg/m^2 Capsule)</title>
          <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
        </group>
        <group group_id="B3">
          <title>Step I: Group 5 (ATV Final Dose: 310mg/m^2 Powder + RTV)</title>
          <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
        </group>
        <group group_id="B4">
          <title>Step I: Group 5a (ATV Final Dose: 310mg/m^2 Powder + RTV)</title>
          <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
        </group>
        <group group_id="B5">
          <title>Step I: Group 6 (ATV Final Dose: 310mg/m^2 Powder + RTV)</title>
          <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
        </group>
        <group group_id="B6">
          <title>Step I: Group 7 (ATV Final Dose: 205mg/m^2 Capsule + RTV)</title>
          <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
        </group>
        <group group_id="B7">
          <title>Step I: Group 8 (ATV Final Dose: 205mg/m^2 Capsule + RTV)</title>
          <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="26"/>
            <count group_id="B6" value="24"/>
            <count group_id="B7" value="14"/>
            <count group_id="B8" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" lower_limit="6.3" upper_limit="12.5"/>
                    <measurement group_id="B2" value="14.3" lower_limit="13.1" upper_limit="20.2"/>
                    <measurement group_id="B3" value="1.2" lower_limit="0.3" upper_limit="2.0"/>
                    <measurement group_id="B4" value="0.4" lower_limit="0.3" upper_limit="0.5"/>
                    <measurement group_id="B5" value="4.4" lower_limit="2.0" upper_limit="12.0"/>
                    <measurement group_id="B6" value="9" lower_limit="5.6" upper_limit="12.7"/>
                    <measurement group_id="B7" value="17" lower_limit="13.9" upper_limit="21"/>
                    <measurement group_id="B8" value="7" lower_limit="0.3" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hisp-Regardless of Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unavailable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Count</title>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="374" lower_limit="105" upper_limit="963"/>
                    <measurement group_id="B2" value="286" lower_limit="11" upper_limit="476"/>
                    <measurement group_id="B3" value="1306" lower_limit="392" upper_limit="4875"/>
                    <measurement group_id="B4" value="2125" lower_limit="583" upper_limit="2715"/>
                    <measurement group_id="B5" value="466" lower_limit="62" upper_limit="1537"/>
                    <measurement group_id="B6" value="540" lower_limit="24" upper_limit="1800"/>
                    <measurement group_id="B7" value="334" lower_limit="1" upper_limit="548"/>
                    <measurement group_id="B8" value="457" lower_limit="1" upper_limit="4875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Percent</title>
          <units>percentage of total lymphocytes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" lower_limit="7" upper_limit="36"/>
                    <measurement group_id="B2" value="14" lower_limit="1" upper_limit="39"/>
                    <measurement group_id="B3" value="19" lower_limit="7" upper_limit="53"/>
                    <measurement group_id="B4" value="35" lower_limit="10" upper_limit="46"/>
                    <measurement group_id="B5" value="16" lower_limit="2" upper_limit="34"/>
                    <measurement group_id="B6" value="21" lower_limit="1" upper_limit="43"/>
                    <measurement group_id="B7" value="19" lower_limit="0" upper_limit="40"/>
                    <measurement group_id="B8" value="18" lower_limit="0" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-RNA</title>
          <units>log10 copies/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" lower_limit="3.5" upper_limit="5"/>
                    <measurement group_id="B2" value="4.7" lower_limit="3.6" upper_limit="6.5"/>
                    <measurement group_id="B3" value="5" lower_limit="4.4" upper_limit="5.6"/>
                    <measurement group_id="B4" value="5" lower_limit="5" upper_limit="6.5"/>
                    <measurement group_id="B5" value="4.8" lower_limit="4.1" upper_limit="5.1"/>
                    <measurement group_id="B6" value="4.5" lower_limit="3.4" upper_limit="5"/>
                    <measurement group_id="B7" value="4.3" lower_limit="3.5" upper_limit="5"/>
                    <measurement group_id="B8" value="4.8" lower_limit="3.4" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced a Safety Endpoint of Interest Attributed to ATV</title>
        <description>Total Bilirubin &gt;= 5.1xULN, ECG Events and Other Grade 3+ toxicities attributed to study treatment.
The AEs were graded by the clinicians according to the Division of AIDS (DAIDS) Toxicity Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. Relationship to study treatment was determined by the study team.</description>
        <time_frame>From study entry up to week 96</time_frame>
        <population>Patients accrued at the final recommended dose for each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced a Safety Endpoint of Interest Attributed to ATV</title>
          <description>Total Bilirubin &gt;= 5.1xULN, ECG Events and Other Grade 3+ toxicities attributed to study treatment.
The AEs were graded by the clinicians according to the Division of AIDS (DAIDS) Toxicity Table (see references in the Protocol Section) as follows: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Potentially Life-Threatening, Grade 5=Death. Relationship to study treatment was determined by the study team.</description>
          <population>Patients accrued at the final recommended dose for each group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Bilirubin &gt;= 5.1xULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase in PR Interval-Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase in PR Interval-Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate-Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate-Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase in QTc Interval-Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Grade 3+ Toxicities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Died</title>
        <time_frame>From study entry up to week 96</time_frame>
        <population>Participants accrued at the final recommended dose for each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died</title>
          <population>Participants accrued at the final recommended dose for each group.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death not attributed to ATV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death attributed to ATV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV RNA &lt;400 Copies/mL at Week 24</title>
        <description>Over the duration of the protocol, the assay used to determine Plasma HIV RNA levels was transitioned from the Amplicor HIV-1 Assay to the Amplicor HIV-1 Monitor 1.5 UltraSensitive Assay (Roche Molecular Systems, Branchburg, NJ) to finally the Abbott Real time HIV-1 RNA assay. The assays were performed according to the manufacturer’s instructions in a laboratory accredited by the College of American Pathologists and certified by the NIH Virology Quality Assurance (VQA) in the United States, and VQA certified in South Africa.</description>
        <time_frame>Week 24</time_frame>
        <population>Participants accrued at the final recommended dose for each group (with evaluable HIV-RNA data).
Virologic response, defined as achieving HIV-RNA &lt; 400 copies/mL and remaining on treatment, was analyzed using an ‘intent-to-treat’ (ITT) approach, in which children who discontinued study treatment for any reason were considered failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6 : ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV RNA &lt;400 Copies/mL at Week 24</title>
          <description>Over the duration of the protocol, the assay used to determine Plasma HIV RNA levels was transitioned from the Amplicor HIV-1 Assay to the Amplicor HIV-1 Monitor 1.5 UltraSensitive Assay (Roche Molecular Systems, Branchburg, NJ) to finally the Abbott Real time HIV-1 RNA assay. The assays were performed according to the manufacturer’s instructions in a laboratory accredited by the College of American Pathologists and certified by the NIH Virology Quality Assurance (VQA) in the United States, and VQA certified in South Africa.</description>
          <population>Participants accrued at the final recommended dose for each group (with evaluable HIV-RNA data).
Virologic response, defined as achieving HIV-RNA &lt; 400 copies/mL and remaining on treatment, was analyzed using an ‘intent-to-treat’ (ITT) approach, in which children who discontinued study treatment for any reason were considered failures.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="43" upper_limit="85"/>
                    <measurement group_id="O2" value="44" lower_limit="24" upper_limit="65"/>
                    <measurement group_id="O3" value="57" lower_limit="34" upper_limit="78"/>
                    <measurement group_id="O4" value="44" lower_limit="14" upper_limit="79"/>
                    <measurement group_id="O5" value="85" lower_limit="65" upper_limit="96"/>
                    <measurement group_id="O6" value="67" lower_limit="45" upper_limit="84"/>
                    <measurement group_id="O7" value="38" lower_limit="14" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV RNA &lt;400 Copies/mL at Week 48</title>
        <description>Over the duration of the protocol, the assay used to determine Plasma HIV RNA levels was transitioned from the Amplicor HIV-1 Assay to the Amplicor HIV-1 Monitor 1.5 UltraSensitive Assay (Roche Molecular Systems, Branchburg, NJ) to finally the Abbott Real time HIV-1 RNA assay. The assays were performed according to the manufacturer’s instructions in a laboratory accredited by the College of American Pathologists and certified by the NIH Virology Quality Assurance (VQA) in the United States, and VQA certified in South Africa.</description>
        <time_frame>Week 48</time_frame>
        <population>Participants accrued at the final recommended dose for each group (with evaluable HIV-RNA data).
Virologic response, defined as achieving HIV-RNA &lt; 400 copies/mL and remaining on treatment, was analyzed using an ‘intent-to-treat’ (ITT) approach, in which children who discontinued study treatment for any reason were considered failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV RNA &lt;400 Copies/mL at Week 48</title>
          <description>Over the duration of the protocol, the assay used to determine Plasma HIV RNA levels was transitioned from the Amplicor HIV-1 Assay to the Amplicor HIV-1 Monitor 1.5 UltraSensitive Assay (Roche Molecular Systems, Branchburg, NJ) to finally the Abbott Real time HIV-1 RNA assay. The assays were performed according to the manufacturer’s instructions in a laboratory accredited by the College of American Pathologists and certified by the NIH Virology Quality Assurance (VQA) in the United States, and VQA certified in South Africa.</description>
          <population>Participants accrued at the final recommended dose for each group (with evaluable HIV-RNA data).
Virologic response, defined as achieving HIV-RNA &lt; 400 copies/mL and remaining on treatment, was analyzed using an ‘intent-to-treat’ (ITT) approach, in which children who discontinued study treatment for any reason were considered failures.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="38" upper_limit="82"/>
                    <measurement group_id="O2" value="32" lower_limit="15" upper_limit="54"/>
                    <measurement group_id="O3" value="71" lower_limit="48" upper_limit="89"/>
                    <measurement group_id="O4" value="55" lower_limit="23" upper_limit="83"/>
                    <measurement group_id="O5" value="85" lower_limit="65" upper_limit="96"/>
                    <measurement group_id="O6" value="63" lower_limit="41" upper_limit="81"/>
                    <measurement group_id="O7" value="29" lower_limit="8" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HIV RNA &lt;400 Copies/mL at Week 96</title>
        <description>Over the duration of the protocol, the assay used to determine Plasma HIV RNA levels was transitioned from the Amplicor HIV-1 Assay to the Amplicor HIV-1 Monitor 1.5 UltraSensitive Assay (Roche Molecular Systems, Branchburg, NJ) to finally the Abbott Real time HIV-1 RNA assay. The assays were performed according to the manufacturer’s instructions in a laboratory accredited by the College of American Pathologists and certified by the NIH Virology Quality Assurance (VQA) in the United States, and VQA certified in South Africa.</description>
        <time_frame>Week 96</time_frame>
        <population>Participants accrued at the final recommended dose for each group (with evaluable HIV-RNA data).
Virologic response, defined as achieving HIV-RNA &lt; 400 copies/mL and remaining on treatment, was analyzed using an ‘intent-to-treat’ (ITT) approach, in which children who discontinued study treatment for any reason were considered failures.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HIV RNA &lt;400 Copies/mL at Week 96</title>
          <description>Over the duration of the protocol, the assay used to determine Plasma HIV RNA levels was transitioned from the Amplicor HIV-1 Assay to the Amplicor HIV-1 Monitor 1.5 UltraSensitive Assay (Roche Molecular Systems, Branchburg, NJ) to finally the Abbott Real time HIV-1 RNA assay. The assays were performed according to the manufacturer’s instructions in a laboratory accredited by the College of American Pathologists and certified by the NIH Virology Quality Assurance (VQA) in the United States, and VQA certified in South Africa.</description>
          <population>Participants accrued at the final recommended dose for each group (with evaluable HIV-RNA data).
Virologic response, defined as achieving HIV-RNA &lt; 400 copies/mL and remaining on treatment, was analyzed using an ‘intent-to-treat’ (ITT) approach, in which children who discontinued study treatment for any reason were considered failures.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" lower_limit="26" upper_limit="70"/>
                    <measurement group_id="O2" value="20" lower_limit="7" upper_limit="41"/>
                    <measurement group_id="O3" value="75" lower_limit="51" upper_limit="91"/>
                    <measurement group_id="O4" value="20" lower_limit="1" upper_limit="72"/>
                    <measurement group_id="O5" value="73" lower_limit="52" upper_limit="88"/>
                    <measurement group_id="O6" value="63" lower_limit="41" upper_limit="81"/>
                    <measurement group_id="O7" value="14" lower_limit="2" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC24h)</title>
        <description>Pharmacokinetics were determined by non-compartmental analysis and AUC0–24hr calculated by the linear trapezoidal method.</description>
        <time_frame>Week 1 (Day 7) Intensive PK-24hr (Pre-Dose, 1, 2, 3, 4, 6, 8, and 12 hours post-dose and the following day at 24-hours post-dose)</time_frame>
        <population>Participants with intensive pharmacokinetic (PK) results at the final recommended dose for each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC24h)</title>
          <description>Pharmacokinetics were determined by non-compartmental analysis and AUC0–24hr calculated by the linear trapezoidal method.</description>
          <population>Participants with intensive pharmacokinetic (PK) results at the final recommended dose for each group.</population>
          <units>ng*hr/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40653" lower_limit="25498" upper_limit="49784"/>
                    <measurement group_id="O2" value="51781" lower_limit="43287" upper_limit="78946"/>
                    <measurement group_id="O3" value="44243" lower_limit="27504" upper_limit="69168"/>
                    <measurement group_id="O4" value="38928" lower_limit="12005" upper_limit="54783"/>
                    <measurement group_id="O5" value="52199" lower_limit="39847" upper_limit="76995"/>
                    <measurement group_id="O6" value="45680" lower_limit="35379" upper_limit="55407"/>
                    <measurement group_id="O7" value="42835" lower_limit="37753" upper_limit="56663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Parameter: Minimum Plasma Concentration (C24)</title>
        <description>Pharmacokinetics were determined by non-compartmental analysis. C24 determined visually, except in the instance when the patient re-dosed the study medication prior to the 24 hour blood draw or the 24 hour level was not obtained, in which case the C24 was calculated from the elimination rate (ke) and the last measured concentration.</description>
        <time_frame>Week 1 (Day 7) Intensive PK-24hr (Pre-dose, 1, 2, 3, 4, 6, 8, and 12 hours post-dose and the following day at 24-hours post-dose)</time_frame>
        <population>Participants with intensive pharmacokinetic (PK) results at the final recommended dose for each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: Minimum Plasma Concentration (C24)</title>
          <description>Pharmacokinetics were determined by non-compartmental analysis. C24 determined visually, except in the instance when the patient re-dosed the study medication prior to the 24 hour blood draw or the 24 hour level was not obtained, in which case the C24 was calculated from the elimination rate (ke) and the last measured concentration.</description>
          <population>Participants with intensive pharmacokinetic (PK) results at the final recommended dose for each group.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173" lower_limit="99" upper_limit="317"/>
                    <measurement group_id="O2" value="510" lower_limit="245" upper_limit="761"/>
                    <measurement group_id="O3" value="482" lower_limit="194" upper_limit="627"/>
                    <measurement group_id="O4" value="596" lower_limit="138" upper_limit="810"/>
                    <measurement group_id="O5" value="947" lower_limit="521" upper_limit="1280"/>
                    <measurement group_id="O6" value="575" lower_limit="389" upper_limit="858"/>
                    <measurement group_id="O7" value="885" lower_limit="692" upper_limit="1491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax)</title>
        <description>Pharmacokinetics were determined by non-compartmental analysis and Maximum concentration (Cmax) was determined visually.</description>
        <time_frame>Week 1 (Day 7) Intensive PK-24 hr (Pre-dose, 1, 2, 3, 4, 6, 8, and 12 hours post-dose and the following day at 24-hours post-dose)</time_frame>
        <population>Participants with intensive pharmacokinetic (PK) results at the final recommended dose for each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2 Capsule</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax)</title>
          <description>Pharmacokinetics were determined by non-compartmental analysis and Maximum concentration (Cmax) was determined visually.</description>
          <population>Participants with intensive pharmacokinetic (PK) results at the final recommended dose for each group.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6463" lower_limit="4994" upper_limit="8207"/>
                    <measurement group_id="O2" value="7006" lower_limit="5925" upper_limit="9324"/>
                    <measurement group_id="O3" value="6501" lower_limit="3218" upper_limit="9083"/>
                    <measurement group_id="O4" value="4952" lower_limit="1365" upper_limit="6070"/>
                    <measurement group_id="O5" value="5593" lower_limit="4151" upper_limit="7548"/>
                    <measurement group_id="O6" value="5013" lower_limit="3692" upper_limit="5993"/>
                    <measurement group_id="O7" value="4095" lower_limit="2947" upper_limit="5563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic (PK) Parameter: Clearance (CL/F)</title>
        <description>Pharmacokinetics were determined by non-compartmental analysis and Apparent oral clearance (CL/F) was calculated as ATV dose divided by AUC0–24hr.</description>
        <time_frame>Week 1 (Day 7) Intensive PK-24 hr (Pre-dose, 1, 2, 3, 4, 6, 8, and 12 hours post-dose and the following day at 24-hours post-dose)</time_frame>
        <population>Participants with intensive pharmacokinetic (PK) results at the final recommended dose for each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: Clearance (CL/F)</title>
          <description>Pharmacokinetics were determined by non-compartmental analysis and Apparent oral clearance (CL/F) was calculated as ATV dose divided by AUC0–24hr.</description>
          <population>Participants with intensive pharmacokinetic (PK) results at the final recommended dose for each group.</population>
          <units>L/hr/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="10.6" upper_limit="21.1"/>
                    <measurement group_id="O2" value="11.4" lower_limit="7.5" upper_limit="14.2"/>
                    <measurement group_id="O3" value="7.9" lower_limit="5.1" upper_limit="12"/>
                    <measurement group_id="O4" value="8.3" lower_limit="5.6" upper_limit="22.4"/>
                    <measurement group_id="O5" value="5.3" lower_limit="3.8" upper_limit="8.2"/>
                    <measurement group_id="O6" value="4.7" lower_limit="3.9" upper_limit="5.9"/>
                    <measurement group_id="O7" value="4.8" lower_limit="3.4" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4 Count (Cells/mm^3) From Baseline to Week 20</title>
        <time_frame>Baseline, Week 20</time_frame>
        <population>Participants accrued at the final recommended dose for each group (with evaluable CD4 data).
CD4 changes from baseline were calculated in an ‘as-treated’ analysis’ such that only patients who tolerated the study treatment, and who had evaluable data were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Count (Cells/mm^3) From Baseline to Week 20</title>
          <population>Participants accrued at the final recommended dose for each group (with evaluable CD4 data).
CD4 changes from baseline were calculated in an ‘as-treated’ analysis’ such that only patients who tolerated the study treatment, and who had evaluable data were included in this analysis.</population>
          <units>Cells/mm^3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="-138" upper_limit="599"/>
                    <measurement group_id="O2" value="184" lower_limit="-122" upper_limit="449"/>
                    <measurement group_id="O3" value="286" lower_limit="-1388" upper_limit="2306"/>
                    <measurement group_id="O4" value="-294" lower_limit="-858" upper_limit="1779"/>
                    <measurement group_id="O5" value="312" lower_limit="-615" upper_limit="1065"/>
                    <measurement group_id="O6" value="176" lower_limit="-368" upper_limit="935"/>
                    <measurement group_id="O7" value="139" lower_limit="-110" upper_limit="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4 Count (Cells/mm^3) From Baseline to Week 48</title>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Patients accrued to the final recommended dose for each group (with evaluable CD4 data).
CD4 changes from baseline were calculated in an ‘as-treated’ analysis’ such that only patients who tolerated the study treatment, and who had evaluable data were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Count (Cells/mm^3) From Baseline to Week 48</title>
          <population>Patients accrued to the final recommended dose for each group (with evaluable CD4 data).
CD4 changes from baseline were calculated in an ‘as-treated’ analysis’ such that only patients who tolerated the study treatment, and who had evaluable data were included in this analysis.</population>
          <units>Cells/mm^3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" lower_limit="60" upper_limit="590"/>
                    <measurement group_id="O2" value="140" lower_limit="-171" upper_limit="348"/>
                    <measurement group_id="O3" value="74" lower_limit="-912" upper_limit="1056"/>
                    <measurement group_id="O4" value="-232" lower_limit="-480" upper_limit="996"/>
                    <measurement group_id="O5" value="324" lower_limit="-297" upper_limit="1833"/>
                    <measurement group_id="O6" value="157" lower_limit="-306" upper_limit="1006"/>
                    <measurement group_id="O7" value="135" lower_limit="-194" upper_limit="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4 Count (Cells/mm^3) From Baseline to Week 96</title>
        <time_frame>Baseline, Week 96</time_frame>
        <population>Patients accrued to the final recommended dose for each group (with evaluable CD4 data).
CD4 changes from baseline were calculated in an ‘as-treated’ analysis’ such that only patients who tolerated the study treatment, and who had evaluable data were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Count (Cells/mm^3) From Baseline to Week 96</title>
          <population>Patients accrued to the final recommended dose for each group (with evaluable CD4 data).
CD4 changes from baseline were calculated in an ‘as-treated’ analysis’ such that only patients who tolerated the study treatment, and who had evaluable data were included in this analysis.</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366" lower_limit="-114" upper_limit="916"/>
                    <measurement group_id="O2" value="233" lower_limit="92" upper_limit="410"/>
                    <measurement group_id="O3" value="340" lower_limit="-938" upper_limit="1640"/>
                    <measurement group_id="O4" value="-600" lower_limit="-828" upper_limit="-371"/>
                    <measurement group_id="O5" value="317" lower_limit="28" upper_limit="1693"/>
                    <measurement group_id="O6" value="260" lower_limit="-106" upper_limit="1230"/>
                    <measurement group_id="O7" value="293" lower_limit="85" upper_limit="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4 Percent From Baseline to Week 20</title>
        <time_frame>Baseline, Week 20</time_frame>
        <population>Patients accrued to the final recommended dose for each group (with evaluable CD4 data).
CD4 changes from baseline were calculated in an ‘as-treated’ analysis’ such that only patients who tolerated the study treatment, and who had evaluable data were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Percent From Baseline to Week 20</title>
          <population>Patients accrued to the final recommended dose for each group (with evaluable CD4 data).
CD4 changes from baseline were calculated in an ‘as-treated’ analysis’ such that only patients who tolerated the study treatment, and who had evaluable data were included in this analysis.</population>
          <units>percentage of total lymphocytes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="-2" upper_limit="16"/>
                    <measurement group_id="O2" value="6" lower_limit="-5" upper_limit="16"/>
                    <measurement group_id="O3" value="8" lower_limit="-9" upper_limit="22"/>
                    <measurement group_id="O4" value="6" lower_limit="-16" upper_limit="12"/>
                    <measurement group_id="O5" value="11" lower_limit="3" upper_limit="24"/>
                    <measurement group_id="O6" value="7" lower_limit="-7" upper_limit="17"/>
                    <measurement group_id="O7" value="3" lower_limit="-1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4 Percent From Baseline to Week 48</title>
        <time_frame>Baseline, Week 48</time_frame>
        <population>Patients accrued to the final recommended dose for each group (with evaluable CD4 data).
CD4 changes from baseline were calculated in an ‘as-treated’ analysis’ such that only patients who tolerated the study treatment, and who had evaluable data were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Percent From Baseline to Week 48</title>
          <population>Patients accrued to the final recommended dose for each group (with evaluable CD4 data).
CD4 changes from baseline were calculated in an ‘as-treated’ analysis’ such that only patients who tolerated the study treatment, and who had evaluable data were included in this analysis.</population>
          <units>percentage of total lymphocytes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="-3" upper_limit="18"/>
                    <measurement group_id="O2" value="9" lower_limit="-1" upper_limit="15"/>
                    <measurement group_id="O3" value="10" lower_limit="-4" upper_limit="20"/>
                    <measurement group_id="O4" value="0" lower_limit="-14" upper_limit="12"/>
                    <measurement group_id="O5" value="12" lower_limit="-1" upper_limit="30"/>
                    <measurement group_id="O6" value="8" lower_limit="-6" upper_limit="26"/>
                    <measurement group_id="O7" value="5" lower_limit="0" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4 Percent From Baseline to Week 96</title>
        <time_frame>Baseline, Week 96</time_frame>
        <population>Patients accrued to the final recommended dose for each group (with evaluable CD4 data).
CD4 changes from baseline were calculated in an ‘as-treated’ analysis’ such that only patients who tolerated the study treatment, and who had evaluable data were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Step I: Group 3: ATV Dose: 520mg/m^2 Capsule</title>
            <description>Group 3 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 520mg/m^2</description>
          </group>
          <group group_id="O2">
            <title>Step I: Group 4: ATV Dose: 620mg/m^2 Capsule</title>
            <description>Group 4 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule) and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
ATV Final Recommended Dose: 620mg/m^2</description>
          </group>
          <group group_id="O3">
            <title>Step I: Group 5: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5 enrolled participants between 91 days of age and 2 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O4">
            <title>Step I: Group 5a: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 5a enrolled participants between 91 days of age and 180 days of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O5">
            <title>Step I: Group 6: ATV Dose: 310mg/m^2 Powder + RTV</title>
            <description>Group 6 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (powder), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 310mg/m^2</description>
          </group>
          <group group_id="O6">
            <title>Step I: Group 7: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 7 enrolled participants between 2 years and 1 day of age and 13 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
          <group group_id="O7">
            <title>Step I: Group 8: ATV Dose: 205mg/m^2 Capsule + RTV</title>
            <description>Group 8 enrolled participants between 13 years and 1 day of age and 21 years of age. They received ATV (capsule), ritonavir, and two NRTIs.
ATV: Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
Ritonavir: Administered as 100 mg capsules or oral solution.
ATV Final Recommended Dose: 205mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Percent From Baseline to Week 96</title>
          <population>Patients accrued to the final recommended dose for each group (with evaluable CD4 data).
CD4 changes from baseline were calculated in an ‘as-treated’ analysis’ such that only patients who tolerated the study treatment, and who had evaluable data were included in this analysis.</population>
          <units>percentage of total lymphocytes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="1" upper_limit="26"/>
                    <measurement group_id="O2" value="9" lower_limit="3" upper_limit="15"/>
                    <measurement group_id="O3" value="10" lower_limit="1" upper_limit="27"/>
                    <measurement group_id="O4" value="-0.5" lower_limit="-1" upper_limit="0"/>
                    <measurement group_id="O5" value="15" lower_limit="-1" upper_limit="32"/>
                    <measurement group_id="O6" value="10" lower_limit="-10" upper_limit="35"/>
                    <measurement group_id="O7" value="9" lower_limit="4" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first study enrollment (16 November 2000) up to the last off-study visit (15 September 2014)</time_frame>
      <desc>P1020A followed intensive reporting requirements defined in DAIDS Serious Adverse Experience Reporting Manual. AEs graded according to the Division of AIDS (DAIDS) AE Grading Table (see references in the Protocol Section) as follows: Gr 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Potentially Life-Threatening, Gr 5=Death.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 3: ATV 520mg/m^2 Capsule</title>
          <description>2 years and 1 day (731 days or more) to 13 years of age.
ATV capsule + 2 NRTIs
Note: This is the final recommended dose for this group.</description>
        </group>
        <group group_id="E2">
          <title>Group 4: ATV 620mg/m^2 Capsule</title>
          <description>13 years and 1 day to 21 (not including the 22nd birthday) years of age.
ATV capsule + 2 NRTIs
Note: This is the final recommended dose for this group.</description>
        </group>
        <group group_id="E3">
          <title>Group 5: ATV 310mg/m^2 Powder + RTV</title>
          <description>91 days to 2 years of age (less than or exactly 730 days.
ATV powder + ritonavir + 2 NRTIs
Note: This is the final recommended dose for this group.</description>
        </group>
        <group group_id="E4">
          <title>Group 6: ATV 310mg/m^2 Powder + RTV</title>
          <description>2 years and 1 day (731 days or more) to 13 years of age.
ATV powder + ritonavir + 2 NRTIs
Note: This is the final recommended dose for this group.</description>
        </group>
        <group group_id="E5">
          <title>Group 7: ATV 205mg/m^2 Capsule + RTV</title>
          <description>2 years and 1 day (731 days or more) to 13 years of age.
ATV capsule + ritonavir + 2 NRTIs
Note: This is the final recommended dose for this group.</description>
        </group>
        <group group_id="E6">
          <title>Group 8: ATV 205mg/m^2 Capsule + RTV</title>
          <description>13 years and 1 day to 21 (not including the 22nd birthday) years of age.
ATV capsule + ritonavir + 2 NRTIs
Note: This is the final recommended dose for this group.</description>
        </group>
        <group group_id="E7">
          <title>Group 5A: ATV 310mg/m^2 Powder + RTV</title>
          <description>91 to 180 days of age.
ATV powder + ritonavir + 2 NRTIs
Note: This is the final recommended dose for this group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Facial wasting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lipoatrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gingival ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lip ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rectal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rectal lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Helminthic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome associated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Meningitis haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Purulent discharge</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Staphylococcal impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Streptococcal impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tinea capitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tinea faciei</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood calcium abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood calcium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood cholesterol abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood potassium abnormal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood sodium abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood urea abnormal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>High density lipoprotein abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pancreatic enzymes abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Clubbing</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lower extremity mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agoraphobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anger</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Perineal rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vulval disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vulvovaginal rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Laryngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nasal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pharyngeal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Eosinophilic pustular folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Exfoliative rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Facial wasting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lipoatrophy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lipodystrophy acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pityriasis alba</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin plaque</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Umbilical haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urticaria chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In accordance with the Clinical Trials Agreement between NIAID (DAIDS) and company collaborators, NIAID (DAIDS) provides companies with a copy of any abstract, press release, or manuscript prior to submission for publication with sufficient time for company review and comment. The publication/other disclosure can be delayed for up to 30 additional business days for manuscripts and five (5) business days for abstracts, to preserve U.S. or foreign patent or other intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Melissa Allen, Director, IMPAACT Operations Center</name_or_title>
      <organization>Family Health International (FHI 360)</organization>
      <phone>(919) 405-1429</phone>
      <email>mallen@fhi360.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

